Adipotide

A synthetic 26-residue peptidomimetic conjugate of a cysteine-flanked homing nonapeptide and a D-amino acid amphipathic heptapeptide repeat domain.

Molecular Profile

Type
Synthetic peptide (peptidomimetic)
Molecular formula
C₁₁₁H₂₀₆N₃₆O₂₈S₂
Molecular weight
2557.2 g/mol
CAS number
859216-15-2
Amino acids
26
Sequence
CKGGRAKDC-GG-D(KLAKLAK)₂
Modification
Contains two D-enantiomeric (D-amino acid) heptapeptide repeats forming an amphipathic proapoptotic domain; cysteine residues present in the homing motif; linear conjugate connected by a GG linker.

Mechanism & Target Class

Adipotide is a two-module synthetic peptidomimetic conjugate. The N-terminal CKGGRAKDC homing segment is a cysteine-flanked nonapeptide whose paired cysteine residues constrain the loop conformation. A GG dipeptide linker connects it to the C-terminal D(KLAKLAK)₂ domain, a tandem heptapeptide repeat built entirely from D-enantiomeric amino acids that folds into an amphipathic α-helix. Structural studies of the conjugate have characterized the sequence alignment of the CKGGRAKDC motif and the membrane-associating behavior of the amphipathic helical domain in vitro.

Storage & Handling

Lyophilized
Store dry at −20 °C or below, protected from moisture and light.
Handling
Aliquot to avoid repeated freeze-thaw cycles; protect from light and heat.

Primary Database

PubChem CID 163360068 ↗

References (20)

  1. Reviews

    1

    Daquinag A.C., Zhang Y., Kolonin M.G. (2011). Trends Pharmacol Sci

    DOI: 10.1016/j.tips.2011.01.004PubMed 21349592

  2. 2

    Ande S.R., Nguyen K.H., Nyomba B.L.G., Mishra S. (2016). Trends Endocrinol Metab

    DOI: 10.1016/j.tem.2016.05.003PubMed 27312736

  3. 3

    Sibuyi N.R.S., Meyer M., Onani M.O., Skepu A., Madiehe A.M. (2018). Int J Nanomedicine

    DOI: 10.2147/IJN.S173424PubMed 30538468

  4. 4

    Xu Y.X.Z., Bassi G., Mishra S. (2019). Biol Sex Differ

    DOI: 10.1186/s13293-019-0239-5PubMed 31118075

  5. 5

    Fang Y., Kaszuba T., Imoukhuede P.I. (2020). Front Physiol

    DOI: 10.3389/fphys.2020.00831PubMed 32760294

  6. 6

    Cao Y. (2010). Nat Rev Drug Discov

    DOI: 10.1038/nrd3055PubMed 20118961

  7. Clinical

    7

    ClinicalTrials.gov (2012). ClinicalTrials.gov

    NCT01262664

  8. Primary research

    8

    Salameh A., Daquinag A.C., Staquicini D.I., An Z., Hajjar K.A., Pasqualini R., Arap W., Kolonin M.G. (2016). JCI Insight

    DOI: 10.1172/jci.insight.86351PubMed 27468426

  9. 9

    Staquicini F.I., Cardó-Vila M., Kolonin M.G., Treplev M., et al. (2011). PNAS

    DOI: 10.1073/pnas.1114503108PubMed 22049339

  10. 10

    Barnhart K.F., Christianson D.R., Wetterau L., Erickson J.A., et al. (2011). Sci Transl Med

    DOI: 10.1126/scitranslmed.3002621PubMed 22072637

  11. 11

    Kim D.-H., Woods S.C., Seeley R.J. (2010). Diabetes

    DOI: 10.2337/db09-1141PubMed 20103704

  12. 12

    Kolonin M.G., Saha P.K., Chan L., Pasqualini R., Arap W. (2004). Nat Med

    DOI: 10.1038/nm1048PubMed 15133506

  13. 13

    Kim D.-H., Sartor M.A., Bain J.R., Sandoval D., et al. (2012). Diabetes

    DOI: 10.2337/db11-1579PubMed 22733798

  14. 14

    Daquinag A.C., Tseng C., Salameh A., Zhang Y., et al. (2015). Cell Death Differ

    DOI: 10.1038/cdd.2014.148PubMed 25342467

  15. 15

    Daquinag A.C., Tseng C., Zhang Y., Amaya-Manzanares F., et al. (2016). Mol Ther

    DOI: 10.1038/mt.2015.155PubMed 26316391

  16. 16

    Gao Z., Daquinag A.C., Yu Y., Kolonin M.G. (2022). Diabetes

    DOI: 10.2337/db21-0972

  17. 17

    Hossen M.N., Kajimoto K., Akita H., Hyodo M., Harashima H. (2012). J Control Release

    DOI: 10.1016/j.jconrel.2012.09.002PubMed 22982237

  18. 18

    Bacher S., Achatz G., Schmitz M.L., Lamers M.C. (2002). Biochimie

    DOI: 10.1016/S0300-9084(02)00027-5PubMed 12628297

  19. 19

    Bahmani T., Sharifzadeh S., Tamaddon G., et al. (2021). J Biomed Phys Eng

    DOI: 10.31661/jbpe.v0i0.905PubMed 33937129

  20. 20

    Su F., Ahn S., Saha A., DiGiovanni J., Kolonin M.G. (2019). Oncogene

    DOI: 10.1038/s41388-018-0558-8PubMed 30361686